Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

The antineoplastic agent cis-diammineplatinum(II) dichloride (cisplatin, CDDP) is part of the poorly effective standard treatment of non-small cell lung carcinoma (NSCLC). Here, we report a novel strategy to improve the efficacy of CDDP. In conditions in which CDDP alone or either of two PARP inhibi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Michels, Judith, Vitale, Ilio, Senovilla, Laura, Enot, David P., Garcia, Pauline, Lissa, Delphine, Olaussen, Ken A., Brenner, Catherine, Soria, Jean-Charles, Castedo, Maria, Kroemer, Guido
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2013
Teme:
Extra Views
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637345/
https://ncbi.nlm.nih.gov/pubmed/23428903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.24034
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items